Pouliot, F. et al. 2026. Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases treated in a single Canadian center. Canadian Urological Association Journal. 20, 6 (Feb. 2026). DOI:https://doi.org/10.5489/cuaj.9398.